指南与共识肝病消化道肿瘤与早癌

肝细胞癌系统治疗:EASL立场文件

Systemic treatment of hepatocellular carcinoma: An EASL position paper.
指南 / 共识 · J Hepatol · 2021-07-10

EASL发布立场文件更新肝细胞癌系统治疗推荐,涉及4种口服多靶点酪氨酸激酶抑制剂、1种抗血管生成抗体及4种免疫检查点抑制剂(单药或联合)。对敏感肿瘤且肝功能良好可序贯治疗者,预期生存可超过2年。需根据证据强度及药物安全性与患者特征匹配做治疗决策。

要点

  • 已上市药物包括索拉非尼、仑伐替尼、瑞戈非尼、卡博替尼、雷莫芦单抗及多种免疫检查点抑制剂。
  • 敏感肿瘤且肝功能良好可序贯治疗者预期生存超过2年。
  • 治疗选择需权衡证据强度并将药物安全性与患者特征匹配。

核心结论

  • 本文件修订既往EASL指南,为肝细胞癌系统治疗提供最新推荐。

研究设计与样本

  • EASL立场文件,基于2018年EASL指南后新出现的数据制定。

主要发现

  • 已上市药物包括4种口服多靶点酪氨酸激酶抑制剂(索拉非尼、仑伐替尼、瑞戈非尼、卡博替尼)、1种抗血管生成抗体(雷莫芦单抗)和4种免疫检查点抑制剂(阿替利珠单抗联合贝伐珠单抗、伊匹木单抗联合纳武利尤单抗、纳武利尤单抗单药、帕博利珠单抗单药)。
  • 对敏感肿瘤且肝功能良好可序贯治疗者,预期生存可超过2年。

关键数值与推荐

  • 推荐需基于疗效证据的稳健性,并将药物安全性与患者特征及偏好正确匹配。

临床怎么用

  • 临床医生应依据证据强度及患者特征选择系统治疗方案,并关注序贯治疗的可能性。

局限性

  • 原文未报告具体研究样本量、P值等详细数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The last 5 years have witnessed relevant advances in the systemic treatment of hepatocellular carcinoma. New data have emerged since the development of the EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma in 2018. Drugs licensed in some countries now include 4 oral multi-tyrosine kinase inhibitors (sorafenib, lenvatinib, regorafenib and cabozantinib), 1 anti-angiogenic antibody (ramucirumab) and 4 immune checkpoint inhibitors, alone or in combination (atezolizumab in combination with bevacizumab, ipilimumab in combination with nivolumab, nivolumab and pembrolizumab in monotherapy). Prolonged survival in excess of 2 years can be expected in most patients with sensitive tumours and well-preserved liver function that renders them fit for sequential therapies. With different choices available in any given setting, the robustness of the evidence of efficacy and a correct matching of the safety profile of a given agent with patient characteristics and preferences are key in making sound therapeutic decisions. The recommendations in this document amend the previous EASL Clinical Practice Guidelines and aim to help clinicians provide the best possible care for patients today. In view of several ongoing and promising trials, further advances in systemic therapy of hepatocellular carcinoma are foreseen in the near future and these recommendations will have to be updated regularly.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Bruix J, Chan SL, Galle PR, et al. Systemic treatment of hepatocellular carcinoma: An EASL position paper. J Hepatol. 2021. PMID: 34256065. doi:10.1016/j.jhep.2021.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。